Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• 主要な著者: Ju Li (著者), Zhongyuan Zhang (著者), Xinhua Wu (著者), Jie Zhou (著者), Deqian Meng (著者), Ping Zhu (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...